Hayley Virgil

April 09, 2021

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.

April 08, 2021

A breast surgeon discusses the best practices for breast cancer surgery during the COVID-19 pandemic.

March 18, 2021

Although cancer screening rates and ensuing diagnoses dropped significantly during the height of the COVID-19 pandemic, testing rates from June 2020 through September 2020 have nearly returned to pre-pandemic levels.

March 02, 2021

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

February 06, 2021

Health-related quality of life (HRQoL) was maintained for patients with EGFR-positive non–small cell lung cancer (NSCLC) who received treatment with adjuvant osimertinib (Tagrisso) versus placebo, with no clinically meaningful differences noted between study arms, according to an analysis on patient-reported outcomes (PROs) from the phase 3 ADAURA trial.

January 18, 2021

Mean daily step count during the first 2 weeks of treatment with SM-88 (racemetyrosine) was found to correlate with overall self-reported quality of life (QoL) in patients with metastatic pancreatic cancer.

January 11, 2021

The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, according to the updated results of a phase 1 study (NCT03220347) presented during the 2020 ESMO Virtual Congress.

December 09, 2020

Patients with chronic lymphocytic leukemia (CLL) who received treatment with single-agent acalabrutinib (Calquence) experienced a low incidence of cardiac toxicities leading to treatment discontinuation, according to data from a pooled analysis across 4 clinical trials presented during the 2020 ASH Annual Meeting & Exposition.

November 29, 2020

The advent of 3D printing has led to an exciting revolution in limb salvage surgery for patients with bone tumors and soft tissue sarcomas, and have resulted in more precise resection and high-fidelity reconstruction, according to R. Lor Randall, MD, FACS.

November 07, 2020

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.